Lung Cancer Nsclc clinical trials

Explore recruiting lung cancer nsclc clinical trials.

Recruiting lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Greece, Poland, Italy, Hungary, Germany, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

C5751002 - A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Norway, Belgium, Greece, Poland, Spain, Italy +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)

Romania, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lung Cancer Nsclc trials by city

Lung Cancer Nsclc in Toronto Lung Cancer Nsclc in Vancouver Lung Cancer Nsclc in Montreal Lung Cancer Nsclc in Calgary Lung Cancer Nsclc in Edmonton Lung Cancer Nsclc in Ottawa Lung Cancer Nsclc in Winnipeg Lung Cancer Nsclc in Quebec City Lung Cancer Nsclc in Hamilton Lung Cancer Nsclc in Kitchener Lung Cancer Nsclc in London Lung Cancer Nsclc in Halifax Lung Cancer Nsclc in New York Lung Cancer Nsclc in Los Angeles Lung Cancer Nsclc in Chicago Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease